Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 831486, 13 pages
http://dx.doi.org/10.1155/2012/831486
Research Article

Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development

1Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
2College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI 48109, USA
3Department of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
4Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA
5Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA

Received 2 August 2011; Revised 9 December 2011; Accepted 12 December 2011

Academic Editor: Andre Van Wijnen

Copyright © 2012 Samantha Sayers et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Petrovsky and J. C. Aguilar, “Vaccine adjuvants: current state and future trends,” Immunology and Cell Biology, vol. 82, no. 5, pp. 488–496, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. D. J. Marciani, “Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity,” Drug Discovery Today, vol. 8, no. 20, pp. 934–943, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Ramon, “Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique,” Bulletin de la Société Centrale de Médecine Vétérinaire, vol. 101, pp. 227–234, 1925. View at Google Scholar
  4. G. Ramon, “Procedes pour accroïtre la production des antitoxins,” Annales de l'Institut Pasteur, vol. 40, pp. 1–10, 1926. View at Google Scholar
  5. A. T. Glenny, C. G. Pope, H. Waddington, and V. Wallace, “The antigenic value of toxoid precipitated by potassium-alum,” Journal of Pathology & Bacteriology, vol. 29, pp. 38–45, 1926. View at Google Scholar
  6. J. Freund, J. Casals, and E. P. Hosmer, “Sensitization and antibody formation after injection of tubercle bacili and parafin oil,” Proceedings of the Society for Experimental Biology and Medicine, vol. 37, pp. 509–513, 1937. View at Google Scholar
  7. C. H. Stuart-Harris, “Adjuvant influenza vaccines,” Bulletin of the World Health Organization, vol. 41, no. 3, pp. 617–621, 1969. View at Google Scholar · View at Scopus
  8. A. G. Johnson, S. Gaines, and M. Landy, “Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide,” The Journal of Experimental Medicine, vol. 103, no. 2, pp. 225–246, 1956. View at Google Scholar
  9. F. Ellouz, A. Adam, R. Ciorbaru, and E. Lederer, “Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives,” Biochemical and Biophysical Research Communications, vol. 59, no. 4, pp. 1317–1325, 1974. View at Google Scholar · View at Scopus
  10. F. R. Vogel and M. F. Powell, “A compendium of vaccine adjuvants and excipients,” in Vaccine Design: The Subunit and Adjuvant Approach, M. F. Powell and M. J. Newman, Eds., pp. 141–228, Plenum, New York, NY, USA, 1995. View at Google Scholar
  11. S. L. Giannini, E. Hanon, P. Moris et al., “Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only,” Vaccine, vol. 24, no. 33-34, pp. 5937–5949, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Cox and A. R. Coulter, “Adjuvants—a classification and review of their modes of action,” Vaccine, vol. 15, no. 3, pp. 248–256, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Aguilar and E. G. Rodríguez, “Vaccine adjuvants revisited,” Vaccine, vol. 25, no. 19, pp. 3752–3762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Xiang, T. Todd, K. P. Ku et al., “VIOLIN: vaccine investigation and online information network,” Nucleic Acids Research, vol. 36, no. 1, pp. D923–D928, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Xiang, W. Zheng, and Y. He, “BBP: brucella genome annotation with literature mining and curation,” BMC Bioinformatics, vol. 7, article 347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Yang, S. Sayers, Z. Xiang, and Y. He, “Protegen: a web-based protective antigen database and analysis system,” Nucleic Acids Research, vol. 39, supplement 1, pp. D1073–D1078, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. He, .L Cowell, and A. D. Diehl, “VO: Vaccine Ontology,” in Proceedings of the 1st International Conference on Biomedical Ontology (ICBO '09), Buffalo, NY, USA, July 2009.
  18. R. K. Gupta, “Aluminum compounds as vaccine adjuvants,” Advanced Drug Delivery Reviews, vol. 32, no. 3, pp. 155–172, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. N. W. Baylor, W. Egan, and P. Richman, “Aluminum salts in vaccines—US perspective,” Vaccine, vol. 20, supplement 3, pp. S18–S23, 2002. View at Google Scholar
  20. R. L. Coffman, A. Sher, and R. A. Seder, “Vaccine adjuvants: putting innate immunity to work,” Immunity, vol. 33, no. 4, pp. 492–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. U. Bielinska, K. W. Janczak, J. J. Landers, D. M. Markovitz, D. C. Montefiori, and J. R. Baker Jr., “Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates,” AIDS Research and Human Retroviruses, vol. 24, no. 2, pp. 271–281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. D. T. O'Hagan, R. Rappuoli, E. De Gregorio, T. Tsai, and G. Del Giudice, “MF59 adjuvant: the best insurance against influenza strain diversity,” Expert Review of Vaccines, vol. 10, no. 4, pp. 447–462, 2011. View at Publisher · View at Google Scholar
  23. E. F. Nicholls, L. Madera, and R. E. W. Hancock, “Immunomodulators as adjuvants for vaccines and antimicrobial therapy,” Annals of the New York Academy of Sciences, vol. 1213, no. 1, pp. 46–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. T. J. Athanassiades, “Adjuvant effect of Bordetella pertussis vaccine to sheep erythrocytes in mice: enhancement of cell-mediated immunity by subcutaneous administration of adjuvant and antigen,” Infection and Immunity, vol. 18, no. 2, pp. 416–423, 1977. View at Google Scholar · View at Scopus
  25. S. Bauer and H. Wagner, “Bacterial CpG-DNA licenses TLR9,” Current Topics in Microbiology and Immunology, vol. 270, pp. 145–154, 2002. View at Google Scholar · View at Scopus
  26. G. Leroux-Roels, “Unmet needs in modern vaccinology. Adjuvants to improve the immune response,” Vaccine, vol. 28, supplement 3, pp. C25–C36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Chen and A. Cerutti, “Vaccination strategies to promote mucosal antibody responses,” Immunity, vol. 33, no. 4, pp. 479–491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. J. Oppenheim, A. Togawa, L. Chedid, and S. Mizel, “Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor,” Cellular Immunology, vol. 50, no. 1, pp. 71–81, 1980. View at Google Scholar · View at Scopus
  29. M. E. Pichichero, “Improving vaccine delivery using novel adjuvant systems,” Human Vaccines, vol. 4, no. 4, pp. 262–270, 2008. View at Google Scholar · View at Scopus
  30. S. L. Bernhardt, M. K. Gjertsen, S. Trachsel et al., “Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study,” British Journal of Cancer, vol. 95, no. 11, pp. 1474–1482, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Song, S. Liu, R. J. Adams, and K. W. Leong, “Enhancing efficacy of HIV Gag DNA vaccine by local delivery of GM-CSF in murine and macaque models,” Journal of Interferon and Cytokine Research, vol. 26, no. 6, pp. 380–389, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Jain, S. P. Vyas, and D. V. Kohli, “Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives,” Nanomedicine, vol. 5, no. 3, pp. 334–344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. R. L. Burke, C. Goldbeck, P. Ng, L. Stanberry, G. Ott, and G. van Nest, “The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine,” The Journal of Infectious Diseases, vol. 170, no. 5, pp. 1110–1119, 1994. View at Google Scholar · View at Scopus
  34. N. Garçon, L. Segal, F. Tavares, and M. van Mechelen, “The safety evaluation of adjuvants during vaccine development: the AS04 experience,” Vaccine, vol. 29, no. 27, pp. 4453–4459, 2011. View at Publisher · View at Google Scholar
  35. M. K. MacLeod, A. S. McKee, A. David et al., “Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 19, pp. 7914–7919, 2011. View at Publisher · View at Google Scholar
  36. Y. He, R. Vemulapalli, and G. G. Schurig, “Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type,” Infection and Immunity, vol. 70, no. 5, pp. 2535–2543, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. He, R. Vemulapalli, A. Zeytun, and G. G. Schurig, “Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51,” Infection and Immunity, vol. 69, no. 9, pp. 5502–5508, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Al-Mariri, A. Tibor, P. Mertens et al., “Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant,” Infection and Immunity, vol. 69, no. 8, pp. 4816–4822, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Estevan, C. Gamazo, M. J. Grilló, G. G. del Barrio, J. M. Blasco, and J. M. Irache, “Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice,” Vaccine, vol. 24, no. 19, pp. 4179–4187, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. V. Delpino, S. M. Estein, C. A. Fossati, P. C. Baldi, and J. Cassataro, “Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice,” Vaccine, vol. 25, no. 37-38, pp. 6721–6729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. A. I. Mallick, H. Singha, S. Khan et al., “Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis,” Vaccine, vol. 25, no. 46, pp. 7873–7884, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. A. J. Winter, G. E. Rowe, J. R. Duncan et al., “Effectiveness of natural and synthetic complexes of porine and O polysaccharide as vaccines against Brucella abortus in mice,” Infection and Immunity, vol. 56, no. 11, pp. 2808–2817, 1988. View at Google Scholar · View at Scopus
  43. M. V. Delpino, S. M. Estein, C. A. Fossati, and P. C. Baldi, “Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria,” Clinical and Vaccine Immunology, vol. 14, no. 10, pp. 1296–1301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. He, S. Reichow, S. Ramamoorthy et al., “Brucella melitensis triggers time-dependent modulation of apoptosis and down-regulation of mitochondrion-associated gene expression in mouse macrophages,” Infection and Immunity, vol. 74, no. 9, pp. 5035–5046, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Cassataro, C. A. Velikovsky, L. Bruno et al., “Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting,” Clinical and Vaccine Immunology, vol. 14, no. 7, pp. 869–874, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. K. Bhattacharjee, M. J. Izadjoo, W. D. Zollinger, M. P. Nikolich, and D. L. Hoover, “Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine,” Infection and Immunity, vol. 74, no. 10, pp. 5820–5825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. A. K. Bhattacharjee, L. van de Verg, M. J. Izadjoo et al., “Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein,” Infection and Immunity, vol. 70, no. 7, pp. 3324–3329, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Cassataro, K. A. Pasquevich, S. M. Estein et al., “A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination,” Vaccine, vol. 25, no. 22, pp. 4437–4446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. D. A. Laplagne, V. Zylberman, N. Ainciart et al., “Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides,” Proteins, vol. 57, no. 4, pp. 820–828, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. R. L. Hunter, “Overview of vaccine adjuvants: present and future,” Vaccine, vol. 20, supplement 3, pp. S7–S12, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. Z. Xiang, M. Courtot, R. R. Brinkman, A. Ruttenberg, and Y. He, “OntoFox: web-based support for ontology reuse,” BMC Research Notes, vol. 3, article 175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. F. R. Vogel, “Improving vaccine performance with adjuvants,” Clinical Infectious Diseases, vol. 30, supplement 3, pp. S266–S270, 2000. View at Publisher · View at Google Scholar · View at Scopus